268: Why Affordable Insulin Is a Money Problem, Not a Science Problem with Eric Moyal - Part 2

Why does life-saving insulin cost hundreds of dollars a month for patients, when manufacturing costs are just a fraction of that price? What if the nonprofit model could change everything for affordable access? In the pharmaceutical industry, affordability and access remain two of the biggest hurdles for patients, especially when the economics of essential medicines seem stacked against them. Eric Moyal, founder of Project Insulin, is rewriting the rules of biosimilar development. Coming from...